Compugen Ltd.

Compugen Ltd.

Compugen Ltd.

Overview
Date Founded

1993

Headquarters

Azrieli Center,26 Harokmim Street,Building D,Holon, Tel Aviv 58858

Type of Company

Public

Employees (Worldwide)

89

Industries

Biotechnology
Other Business & Consulting Services
Management Consulting
IT Consulting & Services
Hospitals & Patient Services
Medical Support Services
Internet Software & Services
Wholesale: Consumer Non-Durables/Sundries

Company Description

Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses its research and development on immuno-oncology and autoimmune diseases. The company was founded by Eli Mintz, Simchon Faigler, and Amir Natan on February 10, 1993 and is headquartered in Holon, Israel.

Contact Data
Trying to get in touch with decision makers at Compugen Ltd.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President, Chief Executive Officer & Director

Chief Operating & Financial Officer

Chief Scientific Officer

Chief Medical Officer

Senior Vice President, Technology Innovation

Vice President, Research & Discovery

Vice President, Business Development

General Counsel

Investor

Board of Directors

President & Chief Executive Officer at eGenesis, Inc.

President & Director at Synergie Lyon Cancer

President, Chief Executive Officer & Director at Compugen Ltd.

Founder & General Partner at Kedma Capital S H E Ltd.

Founder at Nuvelution Pharma, Inc.

Chief Executive Officer at FutuRx Ltd.

Partner at I.H.C.V Israel Healthcare Ventures Ltd.

Director at Compugen Ltd.

Paths to Compugen Ltd.
Potential Connections via
Relationship Science
You
Compugen Ltd.
Owners & Shareholders
Details Hidden

Nikko AMA's investment advice is based on the objectives and terms set out in individual client investment management agreements, relevant fund prospectuses or offering memoranda. Specialist teams throughout the Nikko AM Group's global network are dedicated to providing analysis on macro-economic factors, specific asset classes, strategies and styles. The firm's investment strategy group provides macro-economic insight on factors influencing markets, working in conjunction with investment professionals throughout the group's global network. Equity analysts are assigned responsibilities based on geographic regions, sectors or investment styles. The Nikko AM Group's general approach focuses on fundamental bottom up analysis; although it will vary depending on specific requirements of the investment strategy pursued and is tailored accordingly.

Details Hidden

ARK Investment Management is a registered investment adviser and privately held investment firm, specializing in thematic investing. The firm is rooted in over thirty years of experience in identifying and investing in disruptive innovations that enable outsized growth as industries transform. Through its open source research process, ARK is able to identify companies that it believes are leading and benefiting from disruptive cross-sector forces and changing how the world works.

Details Hidden

Taylor Frigon invests client assets in outstanding companies with excellent growth or income prospects. They take an analytical approach to stock selection, employing both qualitative and quantitative research. The firm invests for the long-term, but maintains disciplined risk management and sell criteria.Taylor Frigon focuses on investing in promising growth companies which clients can own for several years. They look for companies whose financial strength and strategic vision provides maximum potential for long-term capital appreciation. The firm uses traditional fundamental analysis and quantitative metrics to assess a company's business strategy and market position; evaluate its prospects for earnings, revenue growth and margin expansion; and compare its attributes to others in its industry. They seek to purchase outstanding, high-growth businesses, own them for many years and through multiple market cycles until their value is realized.For the income components of portfolios, Taylor Frigon considers companies with growing cash flows and strong balance sheets, along with histories of dividend increases. When utilizing bonds, preferred equity or convertibles, they generally take positions in issuers who demonstrate the ability to cover their liabilities with cash flow. Taylor Frigon uses closed end investment companies when opportunities arise to exploit wide discounts to the underlying net asset value and/or provide exceptionally high current yields.

Recent Transactions
Details Hidden

Compugen Ltd. issued Ordinary Shares

Transaction Advisors
Escrow Agent

Advised onCompugen Ltd. issued Ordinary Shares

Underwriter

Advised onCompugen Ltd. issued Ordinary Shares

Underwriter

Advised onCompugen Ltd. issued Ordinary Shares

Legal Advisor

Advised onCompugen Ltd. issued Ordinary Shares

Legal Advisor

Advised onCompugen Ltd. issued Ordinary Shares

Legal Advisor

Advised onCompugen Ltd. issued Ordinary Shares

Advisors & Consultants
Advisor

Venture Partner & Senior Advisor at New Enterprise Associates

Advisor

President, Chief Executive Officer & Director at Decibel Therapeutics, Inc.

Publicist

Professional at Burns McClellan, Inc.

Clients

Bayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. As an innovation company, it sets trends in research-intensive areas. Bayer’s products and services are designed to benefit people and improve the quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and acts as a socially and ethically responsible corporate citizen. In fiscal year 2012, Bayer employed 110,500 people and had sales of €39.8 billion. Capital expenditures amounted to €2 billion, R&D expenses to €3 billion.

AstraZeneca Plc is a holding company, which engages in the research, development and manufacturing of pharmaceutical products. The company produces and commercializes medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology, and infectious diseases. Its pipeline consists of azd 4831, azd 8601, medi 6012, tagrisso bloom, durvalumab, selumetinib, lyparza polo, epanova, farxiga and brilinta. The company distributes its products under the following brands: Atacand, Crestor, Onglyza, Nexium, Entocort, Losec, Merrem/Meronem, Carbocaine, Citanest, Diprivan, Marcaine/Sensorcaine. AstraZeneca was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Key Stats and Financials As of 2018
Market Capitalization
$372M
Total Enterprise Value
$74.3M
Earnings Per Share
$-0.41
Revenue
$17.8M
Net Profit
$-22.6M
EBITDA
$-21.8M
EBITDAMargin
-122.66%
Total Debt
$0
Total Equity
$37.2M
Enterprise Value Sales
4.17x
TEVNet Income
-3.29x
Debt TEV
0x
Three Year Compounded Annual Growth Rate Of Revenue
21.1%
Five Year Compounded Annual Growth Rate Of Revenue
37.96%
Investors
Details Hidden

Bristol-Myers Squibb Company Our company has a strong legacy of innovation that began in New York in 1858 when Edward R. Squibb, M.D., founded a pharmaceutical company in Brooklyn, and in 1887 when two friends, William McLaren Bristol and John Ripley Myers purchased a struggling drug manufacturing firm in Clinton. Together, they laid the foundation for our company today — a global BioPharma leader that continues this legacy of innovation.

Details Hidden

Investor at Compugen Ltd.

Suppliers
Bayer AG Medical Support Services | Leverkusen, NW

Bayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. As an innovation company, it sets trends in research-intensive areas. Bayer’s products and services are designed to benefit people and improve the quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and acts as a socially and ethically responsible corporate citizen. In fiscal year 2012, Bayer employed 110,500 people and had sales of €39.8 billion. Capital expenditures amounted to €2 billion, R&D expenses to €3 billion.

XOMA Corp. Pharmaceuticals | BERKELEY, CA

XOMA Corp. engages in the discovery and development of innovative therapeutics derived from platform of antibody technologies. Its products includes X358, X213, X129, and gevokizumab. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Emeryville, CA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Compugen Ltd.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Compugen Ltd.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Compugen Ltd..